Improving translational oncology with better statistics
EXCLI Journal · 21.10.2026 · 25 · 1583-1587
DOI: 10.17179/excli2026-9843 ↗Kurz gefasst
Fachartikel in der Zeitschrift EXCLI Journal, online erschienen am 21.10.2026. Verfasst von Siti Nazihahasma Hassan und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In most empirical studies, each research question is assessed using statistical hypothesis testing, with a P value below the pre-specified significance level (α) providing evidence against the null hypothesis. Whilst reporting P values is common practice, they may only indicate the presence or absence of evidence for a difference. Of the 129 preclinical anticancer studies published in 2025 that were reviewed, 95 performed null hypothesis significance testing, including analysis of variance and/or t tests. Of these, only two reported effect size measures. In particular, several aspects of statistical reporting could be improved in future research to facilitate evidence synthesis and translational oncology.
Zitieren
APA
Hassan, S. N., & Ahmad, W. M. A. W. (2026). Improving translational oncology with better statistics. EXCLI Journal, 25, 1583-1587. https://doi.org/10.17179/excli2026-9843
Vancouver
Hassan SN, Ahmad WMAW. Improving translational oncology with better statistics. EXCLI Journal. 2026;25:1583-1587. doi:10.17179/excli2026-9843
BibTeX
@article{Hassan2026,
author = {Hassan, Siti Nazihahasma and Ahmad, Wan Muhamad Amir W},
title = {Improving translational oncology with better statistics},
journal = {EXCLI Journal},
year = {2026},
volume = {25},
pages = {1583--1587},
doi = {10.17179/excli2026-9843}
}
EUVIMED